Bambusa Therapeutics Completes Oversubscribed $90M Series A Funding Round

Bambusa Therapeutics has effectively finished its oversubscribed Series A funding, amassing about $90 million. This biotechnology company specializes in developing bispecific antibodies for immunological and inflammatory disorders. The funding round was spearheaded by RA Capital Management, with contributions from new investors such as Janus Henderson Investors, Redmile Group, Invus, and ADAR1 Capital Management. Existing investors also partook in the funding.

Citation:
[1] Bambusa Therapeutics Inks Approximately $90M in Series A